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Abstract 
Antibiotics are the most commonly prescribed medicines in global healthcare practice today. Their 
effectiveness is crucial and often life-ƐĂǀŝŶŐŝŶŚƵŵĂŶŝƚǇ ?ƐďĂƚƚůĞĂŐĂŝŶƐƚƉĂƚŚŽŐĞŶƐĂŶĚŝŶĨĞĐƚŝŽƵƐ
diseases. Antibiotic/antimicrobial stewardship strategies and programs have become vital to the 
preservation of effective antibiotics and the optimisation of their use. The South African Society of 
Clinical Pharmacy (SASOCP) has written this guideline to outline the importance, role and purpose of 
pharmacists in such stewardship programmes, both in the public, as well as the private hospital 
sectors in South Africa. It also provides an overview of various approaches to antibiotic preservation, 
behavioural change, stewardship measures, and monitoring strategies. 
Aim 
The South African Society of Clinical Pharmacy (SASOCP) has written this guideline to outline the 
importance, role and purpose of pharmacists in antibiotic stewardship programmes, in both public 
and private hospitals in South Africa. 
Antibiotics are the most commonly prescribed medicines in both the community and hospital health 
care setting and are crucial, life-saving medicines in the fight against infectious diseases1-4. Antibiotic 
utilisation world-wide has increased by 36% between 2000 and 2010, with countries such as China, 
India, and South Africa accounting for 76% of this increase4,5. However, the increasing use of 
antibiotics, including their misuse, has escalated the prevalence of antimicrobial resistance (AMR). 
This poses a devastatingly serious threat to public health as well as increasing costs6-9, with the rise in 
AMR potentially resulting in AMR becoming a leading cause of death worldwide by 2050, reducing 
GDP by 2% to 3.5% and costing up to US$ 100 trillion per year6,10. This requires urgent action across 
all countries and government sectors to reduce the imminent threat6. Importantly, factors 
contributing to the rise of AMR include: incorrect selection of an appropriate agent, incorrect timing 
of administration, insufficient dosing and incorrect duration of therapy11.  
The role of the antibiotic stewardship pharmacist includes the preservation of antibiotics through the 
monitoring, evaluation and guidance of appropriate antibiotic use. This includes review of the so-
called  ? ?Ɛ of optimal antibiotic therapy: right Drug, right Dose, De-escalation to pathogen-directed 
therapy and the right Duration of treatment. This aligns to the aim of antibiotic stewardship (ABS), 
which, by definition, is  ?ĂŶ ŽŶŐŽŝŶŐ effort to optimize antibiotic use in order to improve patient 
outcomes, ensure cost-effective therapy and reduce the adverse consequences of antibiotic usage, 
which includes antimicrobial resistance ?12. 
1.1 Antibiotic stewardship in South Africa (SA) 
Currently, novel antibiotic agents are in short supply and the need to conserve the remaining 
resources of effective antibiotics is of paramount importance6. ABS refers to coordinated 
interventions designed to improve and monitor the appropriate use of antibiotics by promoting the 
selection of the optimal antibiotic agent(s), dose, duration of therapy, and route of administration.  
The goals of ABS can be separated into: optimising therapy for individual patients, preventing overuse 
and misuse of antibiotics and minimising the development of resistance at patient and community 
health levels.  The last six years has seen major shifts in policy towards combatting antibiotic resistance 
4 
 
within the SA health care environment. This culminated in the National Department of Health ?Ɛ 
(NDoH) publication of ^ ?Ɛ Antimicrobial Resistance National Strategy Framework 2014-24 in October 
2014, at a Ministerial Antimicrobial Resistance (AMR) Summit13. One of the strategic objectives of the 
framework was to  ‘ƉƌŽŵŽƚĞ appropriate use of antimicrobials in human and animal ŚĞĂůƚŚ ? through 
ensuring access to safe, effective and affordable antimicrobials, institutionalising antimicrobial 
stewardship programmes across sectors, and addressing the use of antimicrobials in animal health 
and crop production. Parallel to this, and as part of the ĐŽƵŶƚƌǇ ?Ɛ drive towards quality health care 
service delivery, specific ABS and infection prevention control norms and standards were finalized and 
published for public comment in the Government Gazette, with a view of them becoming enforceable 
regulations14. A need for ABS implementation and monitoring in SA was highlighted in a recent study 
where 47 private hospitals across SA revealed that close to one in every 15 prescriptions contained 
inappropriately prescribed antibiotics and required intervention15. In addition, the study highlighted 
the significant role of SA pharmacists in antibiotic stewardship, since their collective efforts had a 
substantial impact on reducing antibiotic consumption in their respective hospitals. This demonstrates 
the influence that pharmacist-led stewardship programmes can have in settings where infectious 
disease-trained specialists are limited, and when integrated as part of the multi-disciplinary team 
(MDT)15. Current research is being undertaken in public hospitals to assess the situation in this 
important sector. 
1.2 Roles and responsibilities of the antibiotic stewardship program 
members in South Africa 
In the South African context, especially in the public sector, it is difficult to replicate resource-
abundant stewardship models that are mostly driven by medical microbiology teams, infectious 
disease (ID) specialists and epidemiologists16,17. Sustainable and effective antibiotic stewardship 
programs (ASPs) largely depend on monitoring practices, teamwork in developing and implementing 
interventions, and organisational infrastructure16. Consequently, it is critical in the SA context to utilise 
the existing resources of pharmacists, registered nurses (RNs) and other members of the health care 
team, who are well placed to coordinate anti-infective management and improve patient outcomes18. 
For effective ASPs in SA, it is important to recognize the skills within MDTs that can support 
pharmacists to build effective ABS practices within the South African Antimicrobial Resistance 
National Strategy Framework13 and the associated Implementation Plan14. 
For ASPs to be successful, each member of the healthcare team should wholeheartedly execute the 
requirements of their role and responsibilities, resulting in an impactful stewardship program. Figure 
1 displays the potential key roles of the various players in a stewardship program.  
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 Figure 1: The attributes of function within current antimicrobial stewardship models18 
Microbiology 
x Preliminary microbiology results 
and antibiotic adjustment 
x Final culture report and antibiotic 
adjustment 
x Identification of antimicrobial 
resistance 
x Advisory role on ASP progress 
Case Management 
x Monitor and report on progress 
x IV to PO antibiotic switch 
x Length of stay 
x Outpatient management 
Infection Control 
x Triage and appropriate isolation 
x Final culture report and antibiotic 
adjustment 
x Identification of antimicrobial 
resistance 
x Patient education 
x Outpatient management 
x Hand hygiene 
x Isolation precautions 
Pharmacy 
x Accurate allergy history 
x Medication reconciliation 
x Preliminary microbiology results 
and antibiotic adjustment 
x Antibiotic dosing and de-
escalation 
x Adverse events 
x Final culture report and antibiotic 
adjustment 
x IV to PO antibiotic switch 
x Appropriate duration 
x Ensuring medications are 
available timeously for 
administration 
x Patient education 
x Hand hygiene 
x Infection control precautions 
x Pharmacokinetic and dynamics 
adjustments 
Infectious Disease Specialists 
x Accurate allergy history 
x Early and appropriate cultures 
x Timely antibiotic initiation 
x Medication reconciliation 
x Monitor and report on progress 
x Preliminary microbiology results 
and antibiotic adjustment 
x Antibiotic dosing and de-
escalation 
x Adverse events 
x Evaluation of change in patient 
condition 
x Final culture report and antibiotic 
adjustment 
x Identification of antimicrobial 
resistance 
x IV to PO antibiotic switch 
x Patient education 
x Length of stay 
x Outpatient Management 
x Hand hygiene 
Nursing 
x Triage and appropriate isolation 
x Accurate allergy history 
x Early and appropriate cultures 
x Timely antibiotic administration 
x Medication reconciliation 
x Monitor and report on progress 
x Antibiotic dosing and de-
escalation 
x Adverse events 
x Monitor for changes in patient 
condition 
x IV to PO antibiotic switch 
x Patient education 
x Hand hygiene 
x Infection control precautions 
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1.3 The role of the pharmacist in antibiotic stewardship 
Of the 13 416 pharmacists registered in South Africa in 2015, around 37% are practicing in the public 
sector, a number which has steadily grown from around 16% since 200719.  The average density of 
community pharmacies per head of population is around 0.61 per 10 000; however, with the inclusion 
of primary care clinics this nearly reaches the WHO benchmark of 1 clinic per 10 000 residents20.  
Pharmacists can play a key role in the implementation of ASPs and although, to date, in SA this has 
not been a coordinated effort, recent evidence has shown success in the private sector15. 
 
The distribution of healthcare human resources remains inequitable across the private (well-
resourced) and public sectors (poorly resourced) although several initiatives introduced by the 
government have been implemented to draw healthcare professionals into the public sector21. 
Further to this, formal training for ABS has not been defined, nor mandated in SA, and currently the 
role the pharmacist can play in the ABS team would depend on the level of training that he/she has 
received. As custodians of medicine, pharmacists are well placed to lead and drive the antibiotic 
stewardship initiative, not only through audit and data collection, but also through relationship 
building with prescribers to influence crucial prescribing decisions. The scope of a stewardship 
pharmacist, across the various sectors, includes22-24:  
x Driving and coordinating the hospital ASP 
x Antibiotic prescription review 
x Drug expertise 
x Evaluation of the appropriateness of prescribed antibiotics for given indications 
x Dose optimisation 
x Duration optimisation 
x Monitoring, interpretation and follow-up of microbiology results 
x Development, education and maintenance of clinical guidelines  
x Measurement and tracking of stewardship-initiated interventions 
x Measurement and tracking of compliance to institution-specific guidelines 
x Education and training of other health care providers 
x Co-ordination of research on antibiotic stewardship. 
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1.4 Antibiotic Preservation Strategies 
Studies have shown that, rather than a single strategy in isolation, a combination of strategies 
described in this section, should be implemented, to have a sustainable impact on reducing the 
inappropriate use of antibiotics in hospital settings25. 
1.4.1 Formulary restrictions 
The formulary was one of the earliest methods used to directly influence antibiotic utilisation, and 
contain costs when several therapeutic agents from the same class became available26,27. Selecting 
antibiotics to include in a formulary requires the consideration of multiple factors, including: 
knowledge of local resistance patterns, avoiding agents with a similar spectrum of activity with no 
added benefits, drug costs and toxicity, amongst others. Formulary restriction protects agents that 
are more prone to resistance. Nevertheless, this strategy is rather broad and has not been proven to 
prevent overuse of available broad-spectrum antibiotics27. However, this has depended on the 
acceptance and enforcement of formularies and treatment guidance28,29. Consequently, we believe it 
is necessary to combine formularies with other strategies to optimise appropriate use of antibiotics in 
the future. This includes regular reviews of antibiotic use against current guidance and resistance 
patterns, as well as de-escalation strategies. Periodic reviews of the formulary are needed, depending 
on changes in resistance patterns, availability of newer agents, new knowledge of side-effects of the 
recommended antibiotics, and other significant factors27. 
Within the SA public sector, the implementation of the Essential Drugs Lists (EDLs) and Standard 
Treatment Guidelines (STGs) aids in the protection of antibiotics; however, this currently does not 
apply in the private sector. 
1.4.2 Education and guidelines 
Education is the most fundamental strategy by which prescribers may be influenced to adopt and 
maintain proficient prescribing practices27,29,30 and education forms a very important component of 
any ASP26. Education can range from conference presentations, drug utilisation reviews and feedback, 
hospital pharmacy committee newsletters, student and provider teaching sessions, as well as the 
writing and dissemination of peer-reviewed clinical guidelines for certain infectious diseases31.  The 
implementation of guidelines has been shown to improve the probability of appropriate initial 
antibiotic therapy, use of narrower-spectrum antibiotic regimens, earlier intravenous (IV)-to-oral 
switch therapy, and shorter duration of therapies (DOTs)  W without negatively impacting clinical 
outcomes32. Of importance, however, is that guidelines need to be regularly reviewed and updated, 
and most importantly, combined with other educational efforts, as well as direct interventions and 
monitoring of compliance to enhance their implementation in an endeavour to improve future 
care27,33. 
1.4.3 Prior approval/authorisation of protected antibiotics 
Prior approval/authorisation of protected antibiotics is another strategy that can be used to curtail 
antibiotic use, and requires justification for approval from the pharmacy or clinical head of the 
department for the use of certain antibiotics prior to prescription32. This strategy has been identified 
as the most difficult to adhere to by prescribers, even though it can be the most effective in improving 
antibiotic prescribing26. Approval can be obtained in many ways, including: telephonic authorisations, 
antibiotic order forms and direct interactions with prescribers34. However, there can be concerns with 
formulary or antibiotic restrictions that need to be considered and addressed before implementation. 
These include: delays in initiating therapy, prescriber pushback, and unintended increases in the use 
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of unrestricted antibiotics35. To help preserve antibiotic sensitivity, prior authorisation of selected 
antibiotics combined with education of clinicians on criteria for use can ensure appropriate prescribing 
of antibiotics25. For effective implementation of this strategy, support from the hospital 
administration, supply of the necessary resources with persistent efforts from committed and trained 
personnel, together with continuous communication between pharmacists and prescribers, will be 
needed32. 
1.4.4 De-escalation/streamlining 
The persistent use of broad-spectrum antibiotics contributes to the increase in antibiotic-resistant 
pathogens. De-escalation/streamlining is a method used to provide narrow-spectrum, targeted 
therapy following culture sensitivity results33. The duration of antibiotic therapy can be reduced by 
shortening the course or terminating antibiotics if there is no evidence of infection. This is one of the 
most difficult strategies to implement and requires advanced training on the part of the pharmacist. 
The pharmacist must be aware of the full clinical picture of the patient, e.g. infection markers, 
response to treatment and other diagnostic measures before recommending such an intervention27,33. 
1.4.5 Prospective audit and feedback 
Prospective audit and feedback (PAF) is an intervention that reviews antibiotic prescriptions and 
engages the provider after an antibiotic is prescribed. Improvements on antibiotic use, reduction in 
antibiotic resistance and decline in Clostridium difficile infections (CDI) have been seen in PAF 
interventions with no negative influence on patient outcomes. One study, conducted by a clinical 
pharmacist and infectious diseases (ID) physician, led to a 22% decline in the use of parental broad-
spectrum antibiotics32. In the ICU, PAF interventions showed a decrease in meropenem resistance 
and decreased CDI, without affecting mortality32. The success of PAF is determined by the 
infrastructure and resources in place at an institution, as well as relationships and communication 
methods between pharmacists and prescribers. This process can be laborious and often requires 
ward bed-to-bed prescription surveillance. However, many interventions relating to PAF can be 
implemented at the point of dispensing in the pharmacy during evaluation and interpretation of the 
prescription chart. PAF improves antibiotic use and should be a fundamental component of any 
stewardship program32. 
1.4.6 Pharmacokinetic and pharmacodynamic dosage optimisation 
Pharmacology is based on two principles namely, pharmacokinetics (PK) and pharmacodynamics (PD). 
Conventional antibiotic dosing and administration should be optimized in accordance with PK/PD 
principles for clinical efficacy. Emerging data shows that PK/PD-based approaches to antibiotic 
prescribing should not only be used to improve clinical outcomes, but also to reduce AMR through 
favourable dosing as these principles ensure ideal dosing concentrations and the avoidance of 
ineffective sub-therapeutic antibiotic exposure36. 
In SA, PK/PD monitoring and adjustments should be implemented by hospitals for aminoglycosides 
and vancomycin due to inter-individual variation regarding PK/PD parameters. Contributing factors 
include ƚŚĞƉĂƚŝĞŶƚ ?Ɛage, weight, gender, organ function and disease state.  Sub-therapeutic antibiotic 
exposure is a contributing cause of mortality within the critically-ill patient population suffering from 
severe systemic infections, which further stresses the importance of dose-optimisation via PK/PD 
principles for antibiotics32,37,38.  
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1.5 Behavioural change/modifications 
Irrational prescribing is a global problem and interventions based on behavioural science may reduce 
this. There are many factors which can influence prescribing, which include cultural beliefs, 
socioeconomic factors, patient pressure, desire for clinical ĂƵƚŽŶŽŵǇ ĂƐ ǁĞůů ĂƐ  “ƉƌĞƐĐƌŝďŝŶŐ
ĞƚŝƋƵĞƚƚĞ ?; where prescribers are hesitant to alter prescriptions written by their colleagues10. Prior to 
designing and implementing interventions to alter prescribing practices, it is important to conduct 
research regarding the factors which will influence prescribing practices in the specific institution. This 
will assist in determining what barriers will need to be addressed in order to successfully implement 
a particular intervention.  Research has shown that senior colleagues and opinion leaders have more 
of an influence on prescribing practices than local policies and guidelines. Therefore, when designing 
interventions to change prescribing practice, it is imperative to involve senior clinicians and have their 
endorsement for any policy or guideline prior to implementation16. 
A study done by Burger et al in SA stated that the most important intervention to decrease antibiotic 
resistance rates, is education39. Clinicians need to receive education on antibiotic prescribing 
guidelines and policies in their institution, as this will also lead to enhanced effectiveness of 
interventions40. Meeker et al also found that socially motivated interventions, like accountable 
justification and peer comparison, significantly reduces irrational antibiotic prescribing. Such 
interventions resulted in a greater reduction of inappropriate prescribing, than education or 
observation alone40.  
1.6 Antibiotic stewardship measures 
The following antibiotic stewardship measures have been suggested by the South African Best Care 
Always (BCA) campaign and have been adopted by antibiotic stewards around the country. 
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Table I: Antibiotic stewardship measures41  
Challenge Measure WŚĂƌŵĂĐŝƐƚ ?Ɛ
Level of Training 
Interpretation 
Empiric therapy without 
confirmation 
Antibiotics prescribed without 
appropriate cultures 
Pharmacist Diagnostic microbiological cultures need to be 
taken before initiation of antibiotic therapy, to 
perform accurate  ‘drug-bug matching ? and 
ensure the patient is on the most appropriate 
antibiotic for the infecting organism 
Inappropriate choice of 
antibiotic agent 
 ‘Drug-bug matching ? Pharmacist Ensuring that each patient is on the correct 
antibiotic agent as per culture sensitivity 
results 
Inappropriate 
combinations 
Double gram-negative cover, 
double gram-positive cover, 
double antifungal cover, or 
double anaerobic agents 
Pharmacist Generally, more than one agent from each 
class should not be used simultaneously (i.e. 
two anti-gram-positive agents, two 
antifungals; some antibiotic agents have 
anaerobic cover and the addition of 
metronidazole is considered double anaerobic 
cover; exceptions to this rule include double 
gram-negative cover for certain gram-negative 
infections, e.g. CRE 
Polypharmacy pertaining 
to antibiotics 
The concurrent administration 
of four or more antibiotics 
Pharmacist The concurrent administration of > 4 antibiotic 
agents is rarely considered appropriate. 
Duplication of spectrum of activity is a concern 
when a higher number of antibiotics are used 
concurrently and thus requires review. 
Failure to de-escalate Streamlining therapy from a 
broad-spectrum agent to a 
narrower-spectrum agent 
following culture sensitivity 
results 
Advanced level 
training 
Continuation of broad-spectrum therapy 
following evidence of sensitivity to a narrower 
spectrum agent can contribute to an increased 
risk of antibiotic resistance  
Excessive duration of 
treatment 
 
7-14 days Pharmacist Only in rare circumstance will treatment be 
necessary for > 7 days, i.e. bone sepsis, 
endocarditis, known infections with MRSA, C. 
difficile, etc. 
Inappropriate surgical 
prophylaxis 
Correct agent at the correct 
dose, given at the correct time 
for the correct duration 
Pharmacist Improvement in compliance to appropriate 
antibiotic prophylaxis has been shown to 
decrease post-surgical site infections 
 
IV-to-oral switch (IVOST) Agents which are 100% 
bioavailable can be switched 
interchangeably  
Criteria for switching: 
Improvement in clinical status 
of patient 
Tolerate oral feeds 
Improvement of sepsis markers 
Oral formulation available 
Pharmacist They include: quinolones, voriconazole, 
linezolid, clindamycin, erythromycin, 
clarithromycin, metronidazole, fluconazole  
 
 
Hang-time Hang time refers to the 
difference in time between the 
writing of the antibiotic 
prescription and the time it is 
first administered  
Pharmacist There is 7.6% mortality with every 1-hour 
delay in antibiotic administration for patients 
with sepsis and septic shock.Thus, hang-time 
should ideally not be longer an hour in 
duration, for the first dose of antibiotics 
 
[CRE: Carbapenem-Resistant  Enterobacteriaceae] 
 
1.6.1 Quantifying antibiotic stewardship outcomes 
Currently there is no consensus with regards to which metric best quantifies antibiotic usage in 
hospitals. Metrics which may be used include Defined Daily Dose (DDD), Days of Therapy (DOT) and 
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Length of Therapy (LOT)42. In ambulatory care, DDD and defined daily doses per 1,000 inhabitants per 
day (DIDs), (DDDs/1000 inhabitants/day) are typically used. In Point Prevalence Studies (PPS), 
antibiotic bed-days are also used.  
1.6.1.1 DDD Ȃ Defined Daily Dose 
The most commonly-used metric is DDD. DDDs are determined by the WHO (World Health 
Organisation) and represent the average daily dose of an antibiotic in an average patient 43. The DDD 
is calculated as the total number of grams of antibiotic agent used divided by the number of grams in 
an average daily dose42. Consequently, DDDs can be used to measure antibiotic consumption and can 
serve as a measure to determine the impact of an ASP. Antibiotic usage in hospitals can be expressed 
as DDDs per 100 or 1000 patient-days. The major advantage of the DDD is the ability to compare 
standardised doses amongst different hospitals, as well as different ambulatory care settings within 
and across countries. The disadvantage of the DDD is that it does not account for alternative dosing 
regimens, such as differences in renal function, gender, age or regimens that have been optimised by 
PK or PD dosing, so this can result in overestimation or underestimation of drug consumption42,44. 
Certain shortcomings have been documented with the DDD method, such as the fact that it does not 
apply to the paediatric population and the administered daily dose usually differs significantly from 
the WHO approved DDD because the minimum inhibitory concentration (MIC) for various organisms 
has increased over time due to the emergence of bacterial resistance45. However, in 2016 the National 
Department of Health (NDoH) endorsed the use of DDD in the surveillance of antibiotic consumption, 
as part of the activities in an ASP outlined for public sector hospitals. The data in each province from 
all central, secondary level, and high-throughput district level hospitals must be presented as defined 
daily doses per hundred patient days (DDD/100 patient days). 
1.6.1.2 DOT - Days of Therapy 
An alternative measure of antibiotic consumption is DOT. DOTs are expressed as the administration 
of a single agent on a given day without taking into consideration the doses administered or the 
strength. For example, if a patient receives one antibiotic for three days, it equals three DOTs. 
Similarly, if a patient received three different antibiotics for three days, it would equal nine DOTs. Both 
DDDs and DOTs are useful for inter-facility comparisons and facility-level monitoring of antibiotic 
consumption42.  Important advantages of DOTs are that they are unaffected by the dosage regimen 
the patient is receiving, can be used for both adult and paediatric populations, and can facilitate a 
comparison between different classes of antibiotics within the same institution. Conversely, a 
disadvantage is that DOT may not give an accurate representation of antibiotics that are administered 
multiple times on the same day32,42,46. 
1.6.1.3 LOT - Length of Therapy 
Length of Therapy (LOT) represents the number of days a patient receives antibiotic therapy. LOT does 
not take into consideration the number of antibiotics the patient received. For example, if a patient 
receives three different antibiotics for three days, it would equal three LOTs. When compared to DOT, 
LOT gives a more accurate estimation of the duration of antibiotic therapy42. An important activity for 
a stewardship programme involves recommendations for LOT based on patient-specific factors. 
Developing written guidelines with specific suggestions for duration, including LOT recommendations 
as part of the preauthorisation or prospective audit and feedback processes, or specifying duration at 
the time of antibiotic ordering, are examples of suitable approaches that may be considered32,46. 
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1.7 Monitoring antibiotic stewardship strategies 
1.7.1 Local prevalent sensitivities and resistance patterns 
An important aspect of ASPs is to identify the current local pathogens that are prevalent in the 
institution during the formulation of policies. Simply following the national guidelines may not always 
be the best option, because not all hospitals will experience the same pathogen prevalence and 
resistance patterns. The pharmacist should play an active role in identifying which antibiotics are most 
frequently used, and sometimes overused, and can collaborate with microbiologists who can provide 
input on hospital-specific pathogens and resistance patterns42. 
1.7.2 Antibiograms 
An antibiogram shows an overall profile of microorganism susceptibility to a specific antibiotic in the 
hospital. Institutional antibiograms will help to develop empiric antibiotic therapy guidelines, which 
become vital whenever there are delays in obtaining microbiology results47. Stratified antibiograms 
include parameters, such as patient location, population and infection site, and can assist in optimising 
treatment recommendations and guidelines. For example, certain resistant organisms may be more 
prevalent in intensive care units (ICU) than in non-ICU settings32. 
When constructing an antibiogram, it is important to control the source of the isolates. For example, 
isolates from outpatient samples should be excluded when constructing an antibiogram for inpatients, 
and vice versa. Microbiologists should always be consulted when trying to establish an antibiogram 
for a hospital, because as strict criteria and rules need to be applied to ensure that the data reflected 
in the antibiogram is valid.  
The Infectious Diseases Society of America (IDSA) supports the use of stratified antibiograms over non-
stratified antibiograms, to assist in the development of relevant guidelines. Whilst evidence that 
stratified antibiograms promotes improved empiric antibiotic therapy is limited, stratification can 
reveal important susceptibility differences32. 
 
1.7.3 Infection control 
The transmission of highly-resistant bacteria from one patient to the next, or from patients to health 
care workers and vice versa, amplifies the problem of resistance. Figure 2 depicts the strategic 
objectives, pertaining to infection prevention and control, per the SA AMR framework strategy13. 
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Figure 2: The strategic objectives, pertaining to infection prevention and control, per the SA AMR 
framework strategy13 
 
They key to minimising such transmissions, is careful attention to infection control practices. Key 
elements of such practices, per the WHO, include48: 
x Appropriate barrier precautions for high risk patients (hand washing, wearing gloves and gowns) 
x Appropriate isolation procedures depending on patient risk 
x Adequate sterilisation and disinfection of supplies and equipment 
x Use of aseptic techniques for medical and nursing procedures 
x Training of healthcare personnel in appropriate sterile techniques and infection control 
procedures 
x Maintaining appropriate disinfection and sanitary control of the hospital environment, including 
the air 
x Provision of sufficient basins and hand/paper towels to regularly wash hands between patient 
contacts 
x Recognition, investigation and management of outbreaks or clusters of infection 
x Surveillance of hospital-acquired infections (HAI) and AMR 
x Guideline development together with the standardisation of effective prevention practices and 
the implementation thereof (i.e. standard operation procedures) 
Strategic objective 3: Enhance infection prevention and control 
Sub-objective 3.1: Prevent new 
infections 
Prevention of infection through wide-
reaching vaccination programmes and 
improvements in water and sanitation 
are also key prevention strategies to 
reduce AMR. Optimising vaccine 
uptake to prevent infection, and 
therefore the need for antibiotics, is 
an important tool in preventing 
resistance. This will be implemented 
though primary prevention and 
promotion activities within the public 
District Health System and private 
health systems. 
Sub-objective 3.2: Prevent and control the spread of 
resistant microorganisms 
Infection Prevention and Control (IPC) in the Healthcare facility is a core 
component of overall quality improvement, which if strengthened 
holistically, will directly and indirectly address the current problem of 
AMR. Controlling the spread of resistant microbes to patients and the 
workforce involves rapid identification and isolation of patients with 
resistant organisms, access to personal protective equipment, and most 
importantly, improvement in hand hygiene. The multi-modal WHO 
ŝŶƚĞƌǀĞŶƚŝŽŶ ‘&ŝǀĞDŽŵĞŶƚƐĨŽƌ,ĂŶĚ,ǇŐŝĞŶĞ ?ǁŝůůďĞĂĚŽƉƚĞĚŝŶĂůů^ ŽƵƚŚ
African healthcare facilities as the gold standard for hand hygiene and the 
implementation of sustained campaigns.  
A key enabler to effective infection control includes sufficient, suitably 
qualified and competent IPC practitioners with defined core skills and 
responsibilities for supporting the implementation of control measures in 
the facility.  
Similarly, although more difficult to implement, interventions focused 
on community awareness of basic infection prevention and hand 
hygiene measures may provide long term benefits and will require a 
national awareness campaign and reinforcement through the direct 
community engagement of Community Healthcare Workers. 
10 
 
x Assessment with feedback regarding IPC. 
Pharmacist should adhere to the appropriate infection prevention and control protocols of the 
hospital whilst conducting bedside surveillance for ABS in the wards. This should include being  ‘Bare 
Below the Elbows ? and adhering to hand hygiene practices between patients and whenever applicable. 
Conclusion 
AMR has become a very real and concerning threat to modern-day healthcare practice. The effective 
management thereof requires a decisive and multifaceted approach, which involves several 
members of the multidisciplinary healthcare team. The pharmacist is ideally positioned, and needs 
to play a central role within this setting, to facilitate and coordinate the implementation and 
monitoring of antimicrobial stewardship programs (ASPs). Effective ASPs are required to preserve 
antibiotics via measures such as formulary restrictions, education and guidelines, pre-authorisations, 
de-escalation procedures, audits, and dose optimisation strategies. The successful implementation 
of such programs will be greatly dependent upon the effective quantification and monitoring of 
stewardship outcomes. 
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